We update dosing guides when new clinical trial data publishes, regulatory status changes, or reconstitution math needs correction
Consider consulting a dermatologist for personalized skincare advice
"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: a randomised, double-blind, placebo-controlled, phase 2a trial." Nature Medicine , 2024
With a benign safety profile through six-month rodent toxicology and toxicology already taken to Phase II clinical evaluation in inflammatory bowel disease (PL 14736), BPC-157 stands as one of the few research peptides with a genuinely deep, reproducible evidence base
Symptoms include arrhythmias, feeding difficulties, hypotonia, lethargy, hypoketotic hypoglycaemia, elevated liver enzymes, and rhabdomyolysis or hepatomegaly, among other conditions [8284]
Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake